Stocktoria

MBX Biosciences, Inc. MBX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-09-13

MBX Biosciences, Inc. statistics & valuation

Market cap$2.5B
P / B6.7×
Return on equity-23.6%
Return on capital-26.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-24.10% -23.60% 202320242025
Shares outstanding
1.3M 33.4M 44.9M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-38.70% -23.10% -22.60% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$31.96 -$5.82 -$2.38 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-22.6%-23.1%-38.7%
Return on equity-23.6%-24.1%44.9%
Current ratio24.6224.1921.26

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.